Edition:
India

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.38USD
19 Jan 2018
Change (% chg)

$0.38 (+2.53%)
Prev Close
$15.00
Open
$15.02
Day's High
$15.47
Day's Low
$14.98
Volume
314,854
Avg. Vol
385,407
52-wk High
$19.94
52-wk Low
$13.44

Select another date:

Tue, Jan 16 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

FDA approves Ironwood Pharma's gout drug

Aug 21 Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.

BRIEF-Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout

* Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout

BRIEF-Ironwood Pharmaceuticals Q2 loss per share $0.30

* Ironwood Pharmaceuticals provides second quarter 2017 investor update

Select another date: